Cyclerion Therapeutics Files 8-K
Ticker: CYCN · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-reporting
TL;DR
Cyclerion filed an 8-K, mostly routine stuff, check exhibits for details.
AI Summary
On April 18, 2024, Cyclerion Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Massachusetts and its principal executive offices are located in Cambridge, MA.
Why It Matters
This filing indicates routine corporate reporting by Cyclerion Therapeutics, Inc. to the SEC, providing updates on their operational and financial documentation.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information about significant risks or material events.
Key Numbers
- 001-38787 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1895370 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- Massachusetts (location) — State of incorporation and principal executive offices
- Cambridge (location) — City of principal executive offices
- April 18, 2024 (date) — Date of report
FAQ
What specific 'Other Events' are reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' reported; it only lists 'Other Events' as an item information category.
What is the primary purpose of this 8-K filing for Cyclerion Therapeutics, Inc. on April 18, 2024?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.
Where are Cyclerion Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.
What is the SEC file number for Cyclerion Therapeutics, Inc.?
The SEC file number for Cyclerion Therapeutics, Inc. is 001-38787.
Does this filing indicate any immediate financial changes or material disclosures beyond routine reporting?
Based on the provided text, it is not possible to determine if there are any immediate financial changes or material disclosures beyond routine reporting, as the content focuses on the filing categories.
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-04-18 16:05:54
Filing Documents
- d805884d8k.htm (8-K) — 23KB
- 0001193125-24-100763.txt ( ) — 145KB
- cycn-20240418.xsd (EX-101.SCH) — 3KB
- cycn-20240418_lab.xml (EX-101.LAB) — 18KB
- cycn-20240418_pre.xml (EX-101.PRE) — 11KB
- d805884d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cyclerion Therapeutics, Inc. Dated: April 18, 2024 By: /s/ Regina Graul Name: Regina Graul Title: President